Skip to search formSkip to main contentSkip to account menu

alogliptin 6.25 MG Oral Tablet [Nesina]

Known as: ALOGLIPTIN BENZOATE 6.25 mg ORAL TABLET, FILM COATED [Nesina], Nesina 6.25 MG (as alogliptin benzoate 8.5 MG) Oral Tablet, Nesina 6.25 MG Oral Tablet 
National Institutes of Health

Related topics

Related topics

16 relations
1-ButanolCroscarmellose SodiumEthanolMagnesium stearate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Elevated Serum C-Reactive Protein Level Is not Associated with Serum Nitric Oxide in Patients with Posttraumatic Stress Disorder.
BACKGROUND The aim of the present study was to evaluate serum nitric oxide (NO) and C reactive protein (CRP) concentration in… 
2016
2016
A guide for using experimental design in chromatographic method development: applied to the analysis of selected anti-diabetic pharmaceutical combinations.
A guide experimental design in chromatographic method development was described and applied successfully to the analysis of… 
Review
2015
Review
2015
Alogliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
The dipeptidyl peptidase-4 inhibitor alogliptin (Nesina®, Vipidia®) is approved in numerous countries worldwide for the treatment… 
2014
2014
Separation of alogliptin enantiomers in cyclodextrin‐modified capillary electrophoresis: A validated method
The single enantiomer drug, alogliptin (Alo, Nesina®) is a novel, orally available and selective dipeptidyl peptidase‐4 inhibitor… 
Review
2011
Review
2011
Alogliptin for the treatment of type 2 diabetes.
  • J. White
  • Drugs of Today
  • 2011
  • Corpus ID: 31038561
The pharmacologic management of type 2 diabetes has changed dramatically in the past two decades. We have moved from a situation… 
Review
2011
Review
2011
[Pharmacological and clinical profile of alogliptin benzoate (NESINA®)].
Review
2010
Review
2010
Alogliptin: a review of its use in the management of type 2 diabetes mellitus.
Alogliptin (Nesina®) is a dipeptidyl peptidase-4 inhibitor that is approved in Japan for the treatment of adult patients with… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)